Medicine
Carbidopa and Levodopa 61.25 mg/245 mg extended-release capsule
Carbidopa and Levodopa 61.25 mg/245 mg extended-release capsule is a generic prescription medicine for oral use, made by 2 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to…
Key facts
- Active ingredient (INN)
- Carbidopa and Levodopa
- Brand
- Sold under the generic name
- Strength
- 61.25 mg/245 mg
- Dosage form
- Extended-release capsule
- Route
- Oral
- Packs
- 100 capsules, 50 pouches
- Manufacturers
- Zydus LifesciencesIndiaRemedyrepack
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F). Store in a tightly closed container, protected from light and moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N04BA02 Carbidopa and Levodopa
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 October 2025
- Identifiers
- RxCUI 1600916, 1600773, 1600775 +1DailyMed set ID b29e58f0-67b1-4036-a4a8-4915a8c13cdf, 74e7f96b-de31-4e3c-b32d-11421b291d4eNDC 70518-4610, 70710-2142Application NDA203312
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 capsule, extended release in 1 bottle | 70710-2142-1 | Zydus LifesciencesIndia | 20 October 2025 |
| 50 pouch in 1 box / 1 capsule, extended release in 1 pouch | 70518-4610-0 | Remedyrepack | 23 April 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Carbidopa and Levodopa 61.25 mg/245 mg extended-release capsule.
Other strengths and forms of Carbidopa and Levodopa
Clinical summary
Carbidopa and Levodopa is a fixed-dose combination medicine indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. MedsAcross supplies Carbidopa and Levodopa for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Carbidopa and LevodopaFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- SINEMET prescribing information (Organon) · U.S. National Library of Medicine, DailyMed
- Hopledo: European public assessment report (EPAR) · European Medicines Agency
- Onerji: European public assessment report (EPAR) · European Medicines Agency
Need Carbidopa and Levodopa 61.25 mg/245 mg extended-release capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.